Advertisement
Advertisement
ARGX
argenx SE - ADR
865.04
USDSponsored
-10.26
-1.17%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
870.67
+5.63
+0.65%
ARGX Earnings Reports
Positive Surprise Ratio
ARGX beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Oct 22, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.67B
/$7.63
Implied change from Q2 26 (Revenue/ EPS)
+8.13%
/+4.09%
Implied change from Q3 25 (Revenue/ EPS)
+44.73%
/+47.30%
argenx SE - ADR earnings per share and revenue
On Jul 23, 2026, ARGX reported earnings of 7.33 USD per share (EPS) for Q2 26, beating the estimate of 6.29 USD, resulting in a 16.53% surprise. Revenue reached 1.54 billion, compared to an expected 1.47 billion, with a 4.77% difference. The market reacted with a +8.56% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of 7.63 USD, with revenue projected to reach 1.67 billion USD, implying an increase of 4.09% EPS, and increase of 8.13% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Trevi Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+2.22%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
FAQ
What were argenx SE - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, argenx SE - ADR reported EPS of $7.33, beating estimates by 16.53%, and revenue of $1.54B, 4.77% above expectations.
How did the market react to argenx SE - ADR's Q2 2026 earnings?
The stock price moved up 8.56%, changed from $851.72 before the earnings release to $924.60 the day after.
When is argenx SE - ADR expected to report next?
The next earning report is scheduled for Oct 22, 2026.
What are the forecasts for argenx SE - ADR's next earnings report?
Based on 11
analysts, argenx SE - ADR is expected to report EPS of $7.63 and revenue of $1.67B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement